February 7, 2025 – Sinocare Inc., a global leader in diabetes management and chronic disease diagnostics, is pleased to announce that it has successfully defended itself in the High Court of Justice (Chancery Division) of England and Wales against claims brought by Abbott Diabetes Care Inc. regarding trademark infringement and passing off.

In a definitive ruling issued on February 7, 2025, Mr. Justice Richard Smith rejected Abbott’s claims that Sinocare’s iCan i3 Continuous Glucose Monitoring (CGM) system infringed upon Abbott’s three-dimensional trademark (a white and round disc) for its FreeStyle Libre on-body unit (OBU). The court upheld Sinocare’s counterclaims, declaring Abbott’s trademark invalid on two separate bases: (i) it lacked distinctive character and (ii) it was composed of functional features necessary for achieving a technical result.

The decision of the English High Court follows a similar ruling by the Supreme Court of Austria which found Abbott’s trademark was a weak mark, not indicating origin, and that consumers would not be confused between Sinocare’s iCan i3 and Abbott’s products, not least because of the fundamentally different elements of Sinocare’s iCan i3.

In addition, Sinocare had applied to invalidate Abbott’s EU Trade Mark No. 018474232 (also for the shape of Abbott’s OBUs) on the basis that it had been applied for in bad faith, was not distinctive, and that the shape was necessary to achieve a technical function. Following the closing of oral arguments in the English High Court, Abbott totally surrendered the EUTM.  

Each of these decisions marks a significant victory for innovation and fair competition in the medical technology industry, affirming that product designs based on technical functionality cannot be monopolized through trademark protection. The judgments also reinforce the importance of consumer choice in diabetes care, ensuring that advanced CGM solutions remain accessible to users across the UK and beyond.

Sinocare remains committed to delivering accurate, easy-to-use and affordable diabetes management solutions to patients with diabetes worldwide. With this legal clarity, the company will continue its expansion in Europe and globally, offering innovative CGM technologies that enhance the quality of life for individuals living with diabetes.

About Sinocare Inc.

Sinocare is the largest manufacturer of glucose monitoring devices in Asia. Founded in 2002, Sinocare Inc. was the first blood glucose meter company to be listed in China. With a commercial presence in Asia, Europe and North America, Sinocare has expanded internationally through partnerships and acquisitions such as the USA based PTS Diagnostics Inc., Nipro Diagnostic Inc., now known as Trividia Health Inc. Its dedication to innovation in biosensing technology has helped Sinocare become the global 4th largest blood glucose meter manufacturer and one of the leading POCT companies worldwide.

About Sinocare iCan™️ CGM System

Sinocare iCan CGM System is one of the most widely clinically studied continuous glucose monitoring systems in the world.^{1, 2, 3, 4, 5.}

More than 500 people with type 1 and type 2 diabetes have been involved in our world-wide clinical studies, and most clinical study participants have been assessed in sites in either the United States of America or in the Federal Republic of Germany.                   ;      

~ 60.95% of 507 worldwide iCan CGM system clinical study subjects are people living with diabetes in either the USA or in Germany.

iCan CGM clinical study citations

1. Enrolment n=159  a completed study in adults.

2. Enrolment n=134  a completed study in children.

3. Enrolment n=78  a completed study in children.

4. Enrolment n=16  a completed study in adults.

5. Enrolment n=120  a completed study in adults.

For more inquiries, please contact: 

Sinocare Inc. Investor Relations Office

Email: investor@575695.com

Phone: +86 0731-89935529

Website: 575695.com